TRE-515
Advanced Solid Tumors
About Trethera
Trethera is pioneering a novel therapeutic approach by inhibiting the deoxycytidine kinase (dCK) enzyme within the nucleotide salvage pathway, a metabolic process critical for the rapid proliferation of abnormal cells in cancer and autoimmunity. Its lead candidate, TRE-515, has demonstrated favorable safety and biomarker engagement in an initial Phase 1a solid tumor trial and holds FDA Orphan Drug Designation for two indications, positioning it for potential accelerated development. Backed by a team with a proven track record in drug discovery and company building, and supported by non-dilutive NIH grant funding, Trethera is advancing a single-molecule, multi-indication pipeline with a patient-centric focus.
View full company profileAbout Trethera
Trethera is pioneering a novel therapeutic approach by inhibiting the deoxycytidine kinase (dCK) enzyme within the nucleotide salvage pathway, a metabolic process critical for the rapid proliferation of abnormal cells in cancer and autoimmunity. Its lead candidate, TRE-515, has demonstrated favorable safety and biomarker engagement in an initial Phase 1a solid tumor trial and holds FDA Orphan Drug Designation for two indications, positioning it for potential accelerated development. Backed by a team with a proven track record in drug discovery and company building, and supported by non-dilutive NIH grant funding, Trethera is advancing a single-molecule, multi-indication pipeline with a patient-centric focus.
View full company profileAbout Trethera
Trethera is pioneering a novel therapeutic approach by inhibiting the deoxycytidine kinase (dCK) enzyme within the nucleotide salvage pathway, a metabolic process critical for the rapid proliferation of abnormal cells in cancer and autoimmunity. Its lead candidate, TRE-515, has demonstrated favorable safety and biomarker engagement in an initial Phase 1a solid tumor trial and holds FDA Orphan Drug Designation for two indications, positioning it for potential accelerated development. Backed by a team with a proven track record in drug discovery and company building, and supported by non-dilutive NIH grant funding, Trethera is advancing a single-molecule, multi-indication pipeline with a patient-centric focus.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |